Radim Havelek, Pavel Siman, Jana Cmielova, Alena Stoklasova, Jirina Vavrova, Jaromir Vinklarek, Jiri Knizek and Martina Rezacova Pages 615 - 621 ( 7 )
Modern chemotherapy is interested in developing new agents with high efficiency of treatment in low-dose medication strategies, lower side toxicity and stronger specificity to the tumor cells. Vanadocene dichloride (VDC) belongs to the group of the most promising metallocene antitumor agents; however, its mechanism of action and cytotoxicity profile are not fully understood. In this paper we assess cytotoxic effects of VDC in comparison to cisplatin using opposite prototype of cells; human peripheral blood mononuclear (PBMCs) cells and human acute lymphoblastic leukemia cell line (MOLT-4). Our findings showed cytotoxic effect of VDC on leukemia cells, but unfortunately on human peripheral blood mononuclear cells as well. VDC induces apoptosis in leukemia cells; the induction is, however, lower than that of cisplatin, and in contrary to cisplatin, VDC does not induce p53 up-regulation. Cytotoxic effect of VDC on leukemia cells is less pronounced than that of cisplatin and more pronounced in PBMCs than in MOLT-4 cells.
Cisplatin, Cytotoxicity, Leukemia, MOLT-4 Cell Line, Peripheral Blood Mononuclear Cells, Vanadocene Dichloride, metallocene antitumor agents, lymphoblastic leukemia, mononuclear cells, PBMCs
Dept. of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Simkova 870, 500 38 Hradec Kralove, Czech Republic.